Your session is about to expire
← Back to Search
Carboplatin + Paclitaxel + Bevacizumab for Ovarian Cancer
Study Summary
This trial is to see if a new cancer treatment is safe and has fewer side effects than current treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 1301 Patients • NCT03038100Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- I have a serious wound, ulcer, or bone fracture that won't heal.My blood, kidney, liver, brain functions, and blood clotting are all normal.I do not have acute hepatitis or any active infections.I have unstable chest pain.I am currently experiencing active bleeding.I have a history or signs of brain or spinal cord disease.I have previously been treated with a drug called bevacizumab.I have had cancer before, but it was not skin cancer or it was localized breast cancer.My tumor is slow-growing and not highly cancerous.My diagnosis is advanced ovarian, peritoneal, or fallopian tube cancer.I had surgery for ovarian, peritoneal, or fallopian tube cancer with tissue samples taken.My cancer is one of the specified types of epithelial cell cancer.I can take care of myself but might not be able to do heavy physical work.I had surgery for diagnosis within the last 3 months.I have had radiation therapy in my abdomen or pelvis before.I have had treatments other than my first surgery.I have received targeted or hormonal therapy for ovarian cancer.You have had an allergic reaction to polysorbate 80 in the past.I have been diagnosed with cancer in the lining of my uterus at the same time as another primary cancer.I am under 18 years old.
- Group 1: Carboplatin Paclitaxel & Bevacizumab
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research project accommodating participants who are over 50?
"This medical trial has a set of eligibility requirements, with the lower limit being 18 years old and the upper age capped at 90."
Who meets the criteria to participate in this research?
"This trial requires 9 volunteers aged 18-90 with a history of pharmacotherapy. Additionally, applicants must have healthy bone marrow and renal function, normal neurological results; their blood clotting ability needs to be regular, GOG performance status 0-2, and the study entry date cannot exceed 12 weeks since their diagnosis surgery."
Can you elaborate on other investigations made regarding Carboplatin?
"Presently, there are 1,450 studies underway analyzing the efficacy of Carboplatin. Of these trials, 393 are in their third phase and 76483 treatment centres across the globe are participating. The most prolific area for research is Shanghai; however a multitude of other cities also have operations running."
In what contexts is Carboplatin typically employed?
"Carboplatin is a common choice when treating malignant neoplasms, and it has been used to treat locally advanced nonsquamous non-small cell lung cancer, metastatic colorectal cancer (crc), as well as providing conditioning regimens for allogeneic stem cell transplantation therapy."
What safety measures are taken when administering Carboplatin to patients?
"Relative to other medications, the safety of Carboplatin is rated as a 1 due to its current Phase 1 status. That being said, there are some preliminary data that suggests efficacy and minimal risk associated with this drug."
How many participants are currently involved in this trial?
"At this juncture, this trial is not recruiting. Initially posted on October 1st 2010 and last modified in 2016, the study remains inactive. If you are still seeking out studies to join, 694 pharmacological trials currently require participants and 1450 Carboplatin-based research projects accept patients as well."
Are researchers actively searching for participants in this experiment?
"Unfortunately, this clinical trial is not actively enrolling patients at the moment. It was initially posted on October 1st 2010 and its information was last updated on October 12th 2016. Should you be interested in other studies that are currently recruiting participants, 694 trials related to pharmacotherapy and 1450 with Carboplatin have available spots."
Share this study with friends
Copy Link
Messenger